Cancer angiogenesis: Targeting the heel of Achilles

Full text for this resource is not available from the Research Repository.

Dass, Crispin R and Choong, Peter F. M (2008) Cancer angiogenesis: Targeting the heel of Achilles. Journal of Drug Targeting , 16 (6). pp. 449-454. ISSN 1061-186X


Angiogenesis, which usually heralds a poor prognosis for patients, is essential for malignancy. However, this same process is useful in providing a direct and systemic route for the delivery of cytotoxics to the actively growing parts of the tumour. In fact, there is even some merit to stabilising (normalising) the tumour vasculature to aid drug delivery to the deeper recesses of a growing tumour. Additionally, natural biological inhibitors of angiogenesis such as pigment epithelium-derived factor (PEDF) are being developed to test whether they have better activity than older ones such as endostatin. The field of cancer angiogenesis, more than 35 years old now, has seen a few drugs reaching the market, such as Avastinw. However, there have been a multitude of failed ones, due to lack of activity, especially when tested in vivo and some failing at clinical trials. This review looks at the current state of play in the area of cancer angiogenesis, and development of therapies to target it.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.1080/10611860802088523
Subjects Historical > FOR Classification > 1117 Public Health and Health Services
Historical > Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
Historical > SEO Classification > 8608 Human Pharmaceutical Products
Keywords ResPubID18864. cancer, angiogenesis, tumour, drugs, therapies, drug delivery, malignancy
Citations in Scopus 19 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login